Revenio Group Oyj

Revenio Group Corporation announced its schedule for financial reports in 2025, with the financial statements bulletin, half-year report, and interim reports to be released around 9:00 am Finnish time on specified dates. The Annual General Meeting is set for April 10, 2025, with requests to include agenda items due by February 21, 2025. Revenio, a global provider of eye care diagnostic solutions, reported net sales of EUR 96.6 million and an operating profit of EUR 26.3 million in 2023. The company is listed on Nasdaq Helsinki under the trading code REG1V. For more information, contact CFO Robin Pulkkinen.

Revenio Group Corporation reported strong organic growth in the third quarter of 2024, with exchange rate-adjusted net sales increasing 6.2 percentage points faster than reported growth. Despite exchange rate challenges, sales grew across key markets, notably in the US and APAC regions. The company highlighted significant growth in sales of tonometers and fundus imaging devices, with new products like the iCare ST500 and iCare EIDON AF receiving positive market reception and regulatory approvals. Revenio's acquisition of Thirona Retina supports its strategy to enhance eye diagnostics through AI-based solutions. The company continues to focus on its growth strategy for 2024–2026, despite geopolitical risks and limited future visibility. Revenio's financial performance remains strong, with continued investment in innovative eye care solutions.

Revenio Group Corporation announced that its interim report for January-September 2024 will be released on October 31, 2024, at approximately 09:00 a.m. (EET). The report will be accessible on their website. An audiocast and teleconference for analysts and investors will take place at 3:00 p.m. (EET) on the same day, with details for joining provided through registration links. A recording of the audiocast will be available online after the event. Revenio Group is a global provider of eye care diagnostic solutions, offering tools for diagnosing conditions like glaucoma and diabetic retinopathy. In 2023, the company reported net sales of EUR 96.6 million and an operating profit of EUR 26.3 million. Revenio is listed on Nasdaq Helsinki. For more details, contact CFO Robin Pulkkinen.

Revenio Group Corporation announced the launch of the iCare ST500™, a new slit lamp-based tonometer developed by its subsidiary, iCare. The device integrates iCare's rebound tonometry technology into a modern slit lamp design, offering ease of use for practitioners and comfort for patients. Clinical validation shows that the iCare ST500™ provides intraocular pressure (IOP) measurements comparable to the gold standard applanation tonometry, with less variability between repeated tests. The device also features a new SmartCradle for improved connectivity and a rechargeable lithium battery. The iCare ST500™ aims to enhance clinical workflow efficiency and accuracy in IOP measurements. Revenio Group is a global provider of eye care diagnostic solutions, including tonometers and fundus imaging devices, with significant sales and operating profit in 2023. iCare specializes in innovative eye disease diagnostic tools and is part of the Revenio Group, listed on Nasdaq Helsinki.

Revenio Group Corporation announced that its subsidiary, Icare Finland Oy, has acquired Thirona Retina B.V., an AI software company, from Thirona B.V. Icare initially invested EUR 1.9 million in Thirona Retina in 2023 and has now purchased the remaining shares for approximately EUR 4.8 million. This acquisition aligns with Revenio’s strategy to enhance ophthalmic diagnostics through innovative solutions. Thirona Retina’s AI product, RetCAD™, is used for screening eye diseases like diabetic retinopathy and glaucoma. The integration of Thirona Retina is expected to bolster Revenio’s AI-based ophthalmic solutions, improving eye care diagnostics and access globally. Thirona Retina will continue to sell its RetCAD™ solution to other industry vendors and maintain existing collaborations.

Revenio Group Corporation released a stock exchange notification on August 14, 2024, stating that senior manager Kate Taylor received a share-based incentive on August 13, 2024. The transaction involved 333 shares at a unit price of 0 EUR. Revenio Group is a global provider of eye care diagnostic solutions, including devices for diagnosing glaucoma, diabetic retinopathy, and macular degeneration. In 2023, Revenio's net sales were EUR 96.6 million, with an operating profit of EUR 26.3 million. The company is listed on Nasdaq Helsinki under the trading code REG1V. For more information, contact CFO Robin Pulkkinen.

Revenio Group Corporation reported a strong second quarter for 2024, with net sales increasing by 14.2% to EUR 25.4 million and an adjusted operating profit of EUR 6.0 million, representing 23.5% of net sales. The growth was driven by robust sales in the US, EMEA, and APAC regions, particularly in fundus imaging devices and tonometers. The company’s net cash flow from operations was also very strong. The write-off of EUR 0.73 million in capitalizations related to the discontinued Ventica asthma product impacted the reported operating result. The company is focusing on eye care solutions and has several ongoing product development projects, including the iCare MAIA microperimeter successor and the newly launched iCare TONOVET Pro. Revenio's financial guidance for 2024 estimates a net sales growth of 5-10% and sustained good profitability. The company’s balance sheet remains strong with an equity ratio of 74.7% and net debt at EUR -3.0 million. The AGM re-elected Deloitte Oy as auditors and authorized the Board to acquire own shares and issue new shares. Revenio continues to face risks related to competition, cyber threats, geopolitical uncertainties, and economic conditions. Despite these challenges, the company remains committed to its growth targets and strategic focus on integrated eye care solutions.

Revenio Group Corporation announced that its half-year report for January-June 2024 will be published on Thursday, August 8, 2024, at approximately 09:00 a.m. (EEST) on their website. An audiocast and teleconference call for analysts and investors will be held in English at 3:00 p.m. (EEST) on the same day. The audiocast can be accessed online, and participants can join the teleconference by registering through a provided link. After registration, participants will receive the necessary details to join the call. A recording of the audiocast will be available on the company's website after the event. For further information, contact CFO Robin Pulkkinen. Revenio Group is a global provider of eye care diagnostic solutions, with a focus on diagnosing glaucoma, diabetic retinopathy, and macular degeneration. In 2023, the Group reported net sales of EUR 96.6 million and an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki.

Revenio Group Corporation's Board of Directors has decided to issue shares in a directed share issue without payment, based on authorization from the Annual General Meeting on April 4, 2024. The shares will be given to key persons of the subsidiary Icare World Australia Pty Ltd. (formerly Oculo) as part of a long-term incentive and commitment program. This program, covering the years 2021-2023, aims to align the interests of shareholders and participants, support the company's strategy, and enhance long-term value and performance. A maximum of AUD 1,660,000 worth of shares was allocated, calculated at the trading-weighted average price on April 27, 2021. A total of 833 treasury shares will be transferred, leaving the company with 84,309 treasury shares. For more information, contact CFO Robin Pulkkinen. Revenio Group provides eye care diagnostic solutions and reported net sales of EUR 96.6 million and an operating profit of EUR 26.3 million in 2023. The company is listed on Nasdaq Helsinki with the trading code REG1V.

Revenio Group Corporation has issued an initial notification about a share-based incentive received by Bill Östman, a member of the board. The transaction involved 719 shares at a unit price of 0 EUR. Revenio Group is a global provider of eye care diagnostic solutions and is listed on Nasdaq Helsinki. In 2023, the company reported net sales of EUR 96.6 million and an operating profit of EUR 26.3 million.